There are now a number of treatment options available for people with advanced kidney cancer as first- or second-line treatments. This article talks about the importance of keeping the patient’s characteristics and goals in mind when oncologists decide which treatment to use.
“That gives you an idea of which agent to give to them and, when they’re on the agent, you’re making sure that you maintain channels of communication so you can listen to what the side-effect profile is that they’re developing,” said Dr Eric Jonasch, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, who chaired the 2017 OncLive® State of the Science Summit on Genitourinary Cancers. “You can react in a way that the patient can have maximum quality of life; that is critical. It is probably true for all oncology treatments, but it’s especially true for these targeted agents.”
The article also talks about cabozantinib as a first-line treatment, and combinations of cabozantinib with immunotherapy.
Read more here